Vaginal oestrogen, HRT and continence: an Australian overview

For a significant number of Australian women, the link between declining hormone levels and bladder control is poorly understood — yet it profoundly affects quality of life. If you're navigating menopause, perimenopause or post-menopausal urinary symptoms, it's worth knowing that vaginal oestrogen can play a real role in improving continence for women across Australia. Whether you live in metropolitan Sydney or regional Queensland, the good news is that evidence-based treatments, supportive funding schemes and practical everyday solutions are more accessible than ever.

What is vaginal oestrogen and how does it relate to continence?

Vaginal oestrogen is a localised form of hormone therapy applied directly to the vaginal tissue. Unlike systemic hormone replacement therapy (HRT), which circulates throughout the body, vaginal oestrogen delivers a low dose of oestradiol or oestriol to the urogenital area. It comes in several forms — creams, pessaries, tablets and slow-release rings — all of which are available on prescription in Australia.

As oestrogen levels decline during menopause, the tissues of the vagina, urethra and bladder base become thinner, drier and less elastic. This process, known as genitourinary syndrome of menopause (GSM), can weaken the pelvic-floor muscles and the urethral sphincter, making stress incontinence and urge incontinence far more likely. Many Australian women first notice symptoms such as increased urinary frequency, nocturia or small leaks when coughing or exercising.

By restoring oestrogen locally, vaginal oestrogen therapy helps rebuild tissue thickness, improve blood flow and strengthen the supportive structures around the urethra. For many women, this translates into fewer leaks, reduced urgency and a marked improvement in day-to-day confidence.

Who it affects and why it matters in Australia

Urinary incontinence is remarkably common, yet it remains under-reported. Research suggests that a significant share of women aged over 50 experience some degree of bladder leakage, and the prevalence increases with age. In Australia, where the population is ageing rapidly, the impact on the healthcare system — and on individual wellbeing — is substantial.

Women going through natural menopause typically experience this transition between their late forties and mid-fifties, but surgical menopause, certain medications and medical conditions can trigger oestrogen decline earlier. Indigenous Australian women, women in remote communities and those with limited access to specialist services may face additional barriers to diagnosis and treatment.

The emotional toll is significant too. Many women report avoiding social outings, exercise and intimacy because of fear of leakage. In cities like Melbourne, Brisbane and Perth, continence physiotherapy clinics are relatively accessible, but women in regional Australia often rely on telehealth consultations or travel long distances to see a specialist. That's one reason why practical, discreet solutions — including washable incontinence underwear — play such an important role alongside medical treatment.

Risk factors that increase susceptibility

While declining oestrogen is a primary driver, several other factors compound the risk of urinary incontinence in Australian women:

• Vaginal childbirth, especially multiple deliveries or assisted births, which can weaken pelvic-floor muscles over time.
• Obesity and high body-mass index, which place additional pressure on the bladder and pelvic floor.
• Chronic respiratory conditions or a persistent cough, common in women with asthma or allergies.
• High-impact exercise without adequate pelvic-floor conditioning.
• Previous pelvic or gynaecological surgery, including hysterectomy.

Evidence-based care pathways Australians can access

Australia has a well-established framework for managing urinary incontinence, and vaginal oestrogen therapy is a cornerstone of treatment for post-menopausal women. The Royal Australian College of General Practitioners (RACGP) includes vaginal oestrogen in its clinical guidelines for managing genitourinary syndrome of menopause, and the Australasian Menopause Society endorses its use as a first-line therapy for vulvovaginal atrophy and associated urinary symptoms.

Your first step is usually a visit to your GP. Many bulk-billing GPs across Australia can assess your symptoms, rule out other causes such as urinary tract infections, and prescribe vaginal oestrogen if appropriate. Some preparations are listed on the Pharmaceutical Benefits Scheme (PBS), which significantly reduces the out-of-pocket cost. The Therapeutic Goods Administration (TGA) regulates all oestrogen products available in Australia, ensuring they meet strict safety and efficacy standards.

Beyond medication, a referral to a continence physiotherapist is one of the most effective steps you can take. Pelvic-floor muscle training, sometimes combined with biofeedback or electrical stimulation, has strong evidence behind it. Under Medicare Australia, you may be eligible for subsidised allied-health visits through a Chronic Disease Management plan arranged by your GP. This typically allows five sessions per calendar year, which is often enough to establish a solid pelvic-floor exercise programme.

For women with more complex needs, a referral to a urogynaecologist or continence nurse specialist may be warranted. If you're unsure where to start, the National Continence Helpline on 1800 33 00 66 offers free, confidential advice from continence nurse advisors and can point you to services in your area — whether you're in Adelaide, Darwin or a small rural town.

Understanding HRT, vaginal oestrogen and continence together

It's worth distinguishing between systemic HRT and localised vaginal oestrogen, as the two are sometimes confused. Systemic HRT — delivered via tablets, patches or gels — replaces oestrogen (and often progesterone) throughout the body. It's primarily prescribed to manage hot flushes, night sweats and other vasomotor symptoms of menopause. While systemic HRT can have a positive indirect effect on continence by improving overall tissue health, the evidence specifically supporting its use for urinary symptoms is less consistent than for vaginal oestrogen.

Vaginal oestrogen therapy, by contrast, targets the urogenital tissues directly. Because the dose is low and absorption into the bloodstream is minimal, it carries fewer systemic risks and can often be used by women for whom systemic HRT may not be suitable. The Australasian Menopause Society notes that vaginal oestrogen can generally be used long-term, and many women find it effective for years.

Some women benefit from combining systemic HRT with vaginal oestrogen, particularly if vasomotor symptoms and urogenital symptoms coexist. This is a conversation to have with your GP or menopause specialist, who can tailor the treatment to your individual risk profile and health history.

How Orykas washable incontinence underwear supports confidence

Medical treatment takes time to work — vaginal oestrogen, for example, may take several weeks before you notice a meaningful improvement in symptoms. During that period, and for the many women who experience occasional leaks despite treatment, having reliable everyday protection is essential. Here's the thing: purpose-designed washable incontinence underwear can become a valuable part of your management plan.

Orykas offers a range of ultra-absorbent, washable options designed specifically for Australian women. The Women's Lace-Waistband Washable Incontinence Pants combine discreet lace detailing with a built-in absorbent core, making them indistinguishable from regular underwear under clothing. For women who prefer additional tummy support, the Women's High-Waisted Washable Incontinence Pants offer a higher rise and a secure, comfortable fit throughout the day.

If you're looking for value and variety, the 3-Pack Lace Side Incontinence Briefs provide a practical multi-pack option that reduces laundry rotation stress. All Orykas products are shipped Australia-wide, and because they're reusable, they're kinder to both your wallet and the environment compared with single-use pads or disposable pull-ups.

Pairing vaginal oestrogen therapy with quality washable underwear creates a practical, two-pronged approach: the medication addresses the underlying tissue changes, while the underwear provides immediate, day-to-day leak protection and peace of mind.

NDIS, CAPS and funding options for Australians

Managing incontinence can involve ongoing costs — from prescriptions and physiotherapy sessions to continence products. Fortunately, several Australian Government schemes can help offset these expenses:

• Continence Aids Payment Scheme (CAPS): Administered by Services Australia, CAPS provides an annual payment to eligible Australians to help cover the cost of continence products. You'll need a letter from your GP or continence nurse confirming your condition.
• Pharmaceutical Benefits Scheme (PBS): Certain vaginal oestrogen preparations are PBS-listed, reducing the cost to the standard co-payment or the concessional rate if you hold a concession card.
• National Disability Insurance Scheme (NDIS): If your incontinence is related to a qualifying disability, continence products and supports may be funded under your NDIS plan. Speak with your plan manager or support coordinator for details.
• Medicare-subsidised allied health: Through a GP Management Plan (formerly Enhanced Primary Care plan), Medicare rebates can help cover visits to a continence physiotherapist.
• Private health insurance: Many extras covers include rebates for physiotherapy and, in some cases, continence aids. Check with your fund to understand your entitlements.

If you're unsure which scheme applies to your situation, the National Continence Helpline (1800 33 00 66) can help you navigate eligibility and application processes. Many women are surprised to learn how much financial support is available once they ask the right questions.

Frequently asked questions

Is vaginal oestrogen safe to use long-term?

According to the Australasian Menopause Society, vaginal oestrogen in low doses is considered safe for long-term use in most women, including many breast-cancer survivors (though this should always be discussed with your oncologist). Because systemic absorption is minimal, it doesn't carry the same risk profile as oral or transdermal HRT. Your GP can review your individual circumstances and advise on the most appropriate duration of use.

How quickly does vaginal oestrogen improve continence symptoms?

Many women begin to notice improvements in vaginal dryness and urinary frequency within two to four weeks, though it can take up to three months for the full benefit to develop. Consistency is important — vaginal oestrogen works best when used as prescribed, typically twice weekly after an initial loading phase. During this period, wearing washable incontinence underwear provides practical protection while your body responds to treatment.

Can I get vaginal oestrogen on the PBS in Australia?

Yes. Several vaginal oestrogen preparations are listed on the PBS, which means you'll pay only the standard co-payment (or the concessional rate if you hold a Healthcare Card or Pensioner Concession Card). Your GP or pharmacist can confirm which brands are currently PBS-listed and help you choose the most suitable formulation. The TGA website also maintains an up-to-date register of approved products.

What is the difference between vaginal oestrogen and systemic HRT for continence?

Systemic HRT delivers hormones throughout the entire body and is mainly prescribed for vasomotor symptoms such as hot flushes and night sweats. Vaginal oestrogen, on the other hand, is applied directly to the vaginal and urethral tissues, targeting the specific area affected by genitourinary syndrome of menopause. For continence specifically, vaginal oestrogen has stronger and more consistent clinical evidence. Some women use both forms concurrently — this should be guided by a healthcare professional familiar with your full medical history.

This article is informational and doesn't replace advice from your GP, a qualified continence nurse or a specialist.